Cardiovascular Systems (CSI; St. Paul, MN), a medical device company developing and commercializing interventional treatment systems for patients with peripheral and coronary artery disease, has signed an agreement with Aerolase (Tarrytown, NY) to codevelop a new laser atherectomy device for physicians to use in more effectively treating multiple forms of arterial disease.
Scott Ward, CSI's chairman, president, and CEO, says Aerolase's laser technology, which is FDA-cleared for dermatology and medical aesthetic uses, will help to create a significant improvement in the quality of care for patients suffering from peripheral arterial disease and in-stent restenosis.
Under the terms of the agreement, CSI made an undisclosed equity investment in Aerolase and will make additional equity investments as development milestones are met.
For more information, please visit www.csi360.com and www.aerolase.com.
